Glax­it: Flag­ging a loom­ing threat from Gilead and a weak pipeline, Neil Wood­ford is giv­ing up on GSK and pulling out

Af­ter watch­ing Glax­o­SmithK­line grow in­creas­ing­ly ham­pered by a weak pipeline and “stretched” fi­nan­cials, long­time in­vestor Neil Wood­ford has de­cid­ed to quit the phar­ma gi­ant, wor­ried …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.